- Home
- LNSR vs COYA Comparison
LNSR vs COYA Comparison
Compare LNSR & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LNSR | COYA |
|---|---|---|
| Founded | 2004 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Electronics | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.7M | 124.8M |
| IPO Year | 2005 | 2022 |
Fundamental Metrics
Financial Performance| Metric | LNSR | COYA |
|---|---|---|
| Price | $5.94 | $5.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $10.00 | ★ $15.80 |
| AVG Volume (30 Days) | 47.3K | ★ 177.2K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $58,435,000.00 | $7,945,753.00 |
| Revenue This Year | $10.06 | N/A |
| Revenue Next Year | $41.48 | $763.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 9.24 | ★ 123.57 |
| 52 Week Low | $5.06 | $3.71 |
| 52 Week High | $13.47 | $7.75 |
Technical Indicators
Market Signals| Indicator | LNSR | COYA |
|---|---|---|
| Relative Strength Index (RSI) | 47.68 | 63.35 |
| Support Level | $5.25 | $5.18 |
| Resistance Level | $6.34 | $6.22 |
| Average True Range (ATR) | 0.33 | 0.35 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 25.77 | 96.67 |
Price Performance
Historical ComparisonAbout LNSR LENSAR Inc.
LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe and Asia.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.